Health technology assessments published by HAS in July 2022

24

Aug 2022

In July 2022, the French National Authority for Health (HAS) published seven new opinions based on health technology assessment reports:

  • "Evaluation of the use of echoscopy (or targeted clinical ultrasound) by the general practitioner" – the aim was to evaluate the medical situations for which the use of echoscopy or targeted clinical ultrasound would improve the quality of the clinical examination, determine its place in the diagnostic and therapeutic strategy, define the conditions of achievement and the training requirements that accompany it, and evaluate the consequences of its use on the patient care pathway. The HAS concluded that it was impossible to identify the clinical situations for which the use of targeted clinical ultrasound would bring added value to the standard clinical examination in general medicine and proposed the withdrawal of this evaluation from the 2022 work program;
  • "Confocal endomicroscopy for the characterization of pancreatic cystic tumors" – the aim was to assess the benefit/risk of technology, to define its indications and conditions for carrying it out, and to issue an opinion regarding the registration of this procedure in the Common Classification of Medical Procedures (CCAM). The HAS issued an unfavorable opinion (insufficient actual benefit) for the inclusion of the technology in the CCAM;
  • "Detection of gene alterations RET by next-generation sequencing technique (NGS) in non-small cell lung cancer and medullary thyroid cancer" – the aim was to assess the opportunity and conditions of registering the test in the Nomenclature of Medical Biology Procedures (NABM). The HAS published a favorable opinion (sufficient actual benefit and level III of clinical added value) for the registration of the test in the Nomenclature of Medical Biology Procedures (NABM) in specified indications;
  • "Biological diagnosis of urogenital mycoplasmas in lower genital infections" – the request was made by the National Union of Health Insurance Funds (UNCAM) for the registration of two procedures, research by gene amplification test for Mycoplasma genitalium and mutations of resistance of this mycoplasma to macrolides in the Nomenclature of Medical Biology Procedures (NABM), and removal of the procedure for search for mycoplasmas by culture from the NABM, in the context of the diagnosis of lower genital infections (urethritis or cervicitis). The HAS issued a favorable opinion (sufficient actual benefit and level III of clinical added value) for the registration of two tests and the removal from the NABM (insufficient actual benefit) of the act entitled "Mycoplasmas: cultures on special media, counting, characterization" (code: 5253);
  • "Nucleic acid amplification tests (NAAT) to detect infection with the Monkeypox virus" – the request was made by the General Directorate of Health for the opinion on the reimbursement by Health Insurance. The HAS published a favorable opinion (sufficient actual benefit and level III of clinical added value) for the registration of the test in the Nomenclature of Medical Biology Procedures (NABM) in specified indications;
  • "Test for determination of the deficiency status of the homologous recombination pathway (HRD)" – the aim was to assess the test with the goal of inclusion in the Nomenclature of Medical Biology Procedures (NABM). The HAS published a favorable opinion (sufficient actual benefit and level III of clinical added value) for the registration of the test in the NABM in specified indications;
  • "Transcranial magnetic stimulation for the treatment of depression in adults" – the aim was to evaluate the efficacy and tolerance of the conventional protocol of non-invasive transcranial magnetic stimulation in the acute phase of depression as well as in the consolidation phase of unipolar and drug-resistant depression in adults. The HAS issued an unfavorable opinion (insufficient actual benefit) for the inclusion of the transcranial magnetic stimulation (HF-G protocol) in the treatment of resistant depression in adults in the Common Classification of Medical Procedures (CCAM).

See the details in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

25

Jan 2023

On December 31, 2022, the Decree defining the reimbursement of medical telemonitoring activities via the new framework was published in the Official Journal of the French Republic. The Decree determines the methods of evaluation of digital solutions, registration for reimbursement, modification of the registration conditions, removal and invoicing of medical telemonitoring activities, as well as the conditions for setting the reimbursement packages.

Read more

20

Jan 2023

In December 2022, the National Institute for Health and Care Research (NIHR) in England released six MedTech-related reports in its Health Technology Assessment (HTA) Journal, which concerned laser therapy in diabetic macular oedema, EarlyCDT Lung blood test, video-assisted thoracoscopic or open lobectomy, urethral slings for stress urinary incontinence, placental growth factor (PlGF) and sFlt-1 tests, and photobiomodulation in the management of oral mucositis. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

Read more

18

Jan 2023

In January 2023, the updated Pathology Activity Codes (APAT) of the Norwegian Pathology Code system (NORPAT) came into force. Since 2022, APAT codes have been included in the new reimbursement scheme by Helfo (the Norwegian Health Economics Administration) for outpatient pathology services. Five new classified sample materials for cytology and 22 new additional codes for the method of testing were added to the scheme in 2023.

Read more

16

Jan 2023

The revised EBM (German Uniform Evaluation Standard) catalog came into force on January 1, 2023. The most significant changes concern introducing the EBM codes for several IVD tests and further promoting outpatient (day case) surgical services.

Read more

13

Jan 2023

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in December 2022. Nine recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern the device used for neuromodulation, the device for the treatment of benign prostatic hyperplasia, orthopedic devices, as well as medical aids.

Read more